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Hepatic uptake and biliary excretion of organic anions (e.g., bile acids and bilirubin) is mediated by hepatobiliary transport systems. Defects in
transporter expression and function can cause or maintain cholestasis and jaundice. Recruitment of alternative export transporters in coordination
with phase I and II detoxifying pathways provides alternative pathways to counteract accumulation of potentially toxic biliary constituents in
cholestasis. The genes encoding for organic anion uptake (NTCP, OATPs), canalicular export (BSEP, MRP2) and alternative basolateral export
(MRP3, MRP4) in liver are regulated by a complex interacting network of hepatocyte nuclear factors (HNF1, 3, 4) and nuclear (orphan) receptors
(e.g., FXR, PXR, CAR, RAR, LRH-1, SHP, GR). Bile acids, proinflammatory cytokines, hormones and drugs mediate causative and adaptive
transporter changes at a transcriptional level by interacting with these nuclear factors and receptors. Unraveling the underlying regulatory
mechanisms may therefore not only allow a better understanding of the molecular pathophysiology of cholestatic liver diseases but should also
identify potential pharmacological strategies targeting these regulatory networks. This review is focused on general principles of transcriptional
basolateral and canalicular transporter regulation in inflammation-induced cholestasis, ethinylestradiol- and pregnancy-associated cholestasis,
obstructive cholestasis and liver regeneration. Moreover, the potential therapeutic role of nuclear receptor agonists for the management of liver
diseases is highlighted.
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The field of hepatobiliary transport has greatly advanced
since cloning of the major transport systems for bile acids and
other organic anions at the end of the last century. The discovery
of bile acids, bilirubin and a broad range of xenobiotics as
specific ligands for nuclear (orphan) receptors and the assign-
ment of their regulatory role to individual hepatobiliary trans-
porter genes has given way to an area of extensive research over
the past years. Subsequently, a rapidly growing number of pub-
lications have been dealing with regulatory mechanisms of
hepatobiliary transporter gene expression in health and disease.
The transcriptional regulation of hepatic organic anion trans-
porters by liver-enriched hepatocyte nuclear factors and ligand-
activated nuclear receptors is key for understanding the mole-
cular mechanisms of cholestasis. Moreover, transporter changes
at a transcriptional level may represent potential targets for
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view on the transcriptional mechanisms of hepatic organic anion
transporter regulation in liver disease and their potential thera-
peutic implications.
2. Physiology and pathophysiology of hepatobiliary transport
Hepatobiliary transport systems are essential for normal
bile formation and hepatic elimination of various endo- and
xenobiotics including bile acids, bilirubin, cholesterol phos-
pholipids, hormones, drugs and toxins [1–5]. The liver
comprises specific uptake and export systems for these
substrates. Progress over the past decade has resulted in the
molecular identification of most relevant transport systems
involved in normal bile formation and transport in intestine
and kidney [1–5] (Table 1).
2.1. Basolateral organic anion uptake
Hepatic uptake of bile acids is mediated by a high-affinity
Na+-dependent bile salt transporter Ntcp/NTCP (Slc10a1/
SLC10A1) and a family of multispecific organic anion
transporters (Oatps/OATPs; Slc21a/SLC21A) that mediate
Na+-independent uptake of mostly amphipathic organic com-
pounds, including conjugated and unconjugated bile acids,
bromosulphophthalein and bilirubin. Na+-independent bile acid
uptake is quantitatively less important than Na+-dependent
uptake and is largely mediated by facilitated exchange with
intracellular anions (e.g., GSH, HCO3
−). The transport char-
acteristics of Oatp1 (Slc21a1, new nomenclature Oatp1a1),
Oatp2 (Slc21a5, new nomenclature Oatp1a4) and Oatp4
(Slc21a10, new nomenclature Oatp1b2) can account for the
bulk of Na+-independent bile acid uptake in rat liver. In
humans, three liver specific OATPs (OATP1, also called
OATP-A (SLC21A3) or new nomenclature OATP1A2; OATP2,
also called OATP-C (SLC21A6) or new nomenclature
OATP1B1; and OATP8(SLC21A8) or new nomenclature
OATP1B3) transport bile acids. In order to avoid confusions
it is important to keep in mind that the numbering of human
OATPs does not indicate that these transporters are human
orthologues of the rodent Oatp with the same number (Table 1)
[6]. In addition to these uptake systems, the basolateral
membrane also contains efflux pumps. Mrp3/ MRP3 (Abcc3/
ABCC3) and Mrp4/MRP4 (Abcc4/ABCC4) are normally
expressed at very low levels in hepatocytes, but are upregulated
in cholestasis which may explain the shift towards renal
excretion of bile acids in patients with chronic, longstanding
cholestasis [7–14]. Members of the Oatp/OATP family also
remain candidates for bile acid efflux at the basolateral mem-
brane, since Oatp1 and 2 are able to operate as bi-directional
exchangers. Recently the heteromeric organic solute transporter
Ostα–Ostβ, was identified as an ileal basolateral bile acid
export system [15]. In contrast to mouse Ost α/β which was
detected only in mouse kidney and intestine, mirroring Asbt's
horizontal gradient with highest expression in the distal
gastrointestinal tract, analysis of human OSTα/β also showed
high expression in liver [15,16].2.2. Canalicular and ductular transport: bile-salt dependent
and bile salt-independent bile flow
Bile is primarily formed by canalicular excretion of bile acids
and non-bile acid organic anions via ATP-binding cassette (ABC)
transporters, followed by modification of canalicular bile by the
bile duct epithelium. Canalicular excretion accounts for ∼75% of
daily bile production in man and represents the rate limiting step of
bile secretion. Most canalicular transport proteins for biliary
organic anion and lipid secretion are ATP-binding cassette (ABC)
proteins such as the multidrug resistance (MDR) P-glycoproteins
(ABC-B subfamily) or the multidrug-resistance proteins (MRP)
(ABC-C subfamily) [1]. As such, the canalicular membrane con-
tains a bile salt export pump (Bsep/BSEP; Abcb11/ABCB11) for
monovalent bile acids, a conjugate export pump (Mrp2/MRP2,
Abcc2/ABCC2) for divalent bile acids and various other amphi-
pathic conjugates, including bilirubin diglucuronide and GSH (a
major determinant of bile acid-independent canalicular bile flow), a
multidrug export pump (Mdr1/MDR1, Abcb1/ABCB1) for bulky
amphipathic organic cations (e.g., various drugs), a phospholipid
flippase (Mdr2 in rodents/MDR3 in humans; Abcb4/ABCB4) for
phosphatidylcholine translocation, a ABC-G two half transporter
(ABCG5 and 8) for sitosterol and cholesterol, a P-type ATPase
(Fic1/FIC1; ATP8B1) mutated in hereditary cholestasis whose
substrate/function is still unknown and a Cl−/HCO3
− exchanger
(AE2; SLC4A2) for HCO3
− excretionwhich is the only functionally
relevant ATP-independent transport system at the canalicular
membrane. The vectorial excretion of bile salts into bile by the
export pump BSEP represents the major driving force for bile flow
(“bile salt-dependent” bile flow). Canalicular excretion of reduced
glutathione (GSH) conjugate export pump MRP2 and bicarbonate
(HCO3
−) by the Cl−/HCO3
− exchanger AE2 constitute the major
components of the “bile salt-independent” fraction of bile flow.
However, HCO3
− secretion occurs mainly at the level of bile duct
epithelial cells (cholangiocytes), in response to stimulation by
hormones and neuropeptides. Both hepatocellular and ductular
secretion establish an osmotic gradient that in turn drives passive
transcellular presumably aquaporin-mediated transcellular move-
ment ofwater. Finalmodification of bile in the gallbladder ismainly
the result of active transport of Cl− and HCO3
−, and the passive
aquaporin-mediated transport of water into bile [17]. The quantity
of “ductular/ductal bile” varies fromas little as 5% in rats to asmuch
as 25–40% of secretion in man.
2.3. Cholehepatic shunting and enterohepatic circulation
Many biliary compounds (e.g., bile acids) secreted into bile
undergo an enterohepatic circulation, i.e., are reabsorbed in the
intestine, taken-up again by the liver and secreted into bile. Organic
biliary constituents including bile salts are reabsorbed with high
efficiency after reaching the small intestine and recirculate via the
portal blood back to the liver. Apical bile salt uptake of conjugated
bile salts in the terminal ileum is mediated by the ileal bile salt
transporter Isbt/ISBT (SLC10A2) also known as the apical sodium-
dependent bile salt transporter (Asbt/ASBT) [1,4]. The Na+-
independent bile salt transporter Oatp3 (Slc21a7) is predominantly
located to the apical surface of jejunal epithelial cells but its relative
Table 1
Nomenclature, hepatocellular localization, function and substrates of major hepatobiliary transport systems
Gene Function Substrates
Basolateral membrane
NTCP/Ntcp (SLC10A1/Slc10a1)
Na+/taurocholate cotransporter
Main transporter for Na+-dependent bile acid
uptake from portal blood into hepatocyte
Conjugated and unconjugated bile acids with highest affinity for
conjugated di- and trihydroxy bile acids; estrogen conjugates
(e.g., estrone-3-sulfate), BSP, DHEAS, thyroid hormones, drugs
covalently bound to taurocholate (e.g., chlorambucil)
OATP1A2, OATP-A
(SLCO1A2; SLC21A3) Organic
anion transporting protein
Multispecific organic anion transporter for
Na+-independent uptake of bile acids and a
broad range of other organic anions
and cations; minor contribution to overall
bile acid uptake
Conjugated and unconjugated bile acids, estrogen conjugates,
DHEAS, BSP; neutral steroids such as ouabain, thyroid hormones,
the opioid receptor antagonists D-penicillamine-enkephaline and
deltorphine II, the antihistamine fexofenadine, organic cations such
as ADP-ajmalium, rocuronium and n-methylquinine
OATP1B1, OATP-C
(formerly LST-1) (SLCO1B1;
SLC21A6) Organic anion
transporting protein
Multispecific organic anion transporter for
Na+-independent uptake of bile acids and a
broad range of other organic anions; most
important OATP for bile acid uptake
Similar to OATP1A2: conjugated and unconjugated bile acids,
additionally bilirubin monoglucuronide and unconjugated
bilirubin, LTC4, prostaglandin E2, thromboxane B2, pravastatin,
rifampin
OATP1B3, OATP-8
(SLCO1B3; SLC21A8) Organic
anion transporting protein
Multispecific organic anion transporter for
Na+-independent uptake of bile acids and
a broad range of other organic anions;
role of bile acid transport controversial
Conjugated bile acids; bilirubin monoglucuronide, BSP,
DHEAS, cholecystokinine, estrogen conjugates, thyroid
hormones, D-penicillamine-enkephaline, n-methylquinine,
ouabain, digoxin, rifampin
Oatp1a1, Oatp1
(Slco1a1; Slc21a1) Organic
anion transporting protein
Multispecific organic anion transporter for
Na+-independent uptake of bile acids and
a broad Range of other organic anions;
most important Oatp for bile acid uptake
in rodent liver
Similar to OATP1A2: conjugated and unconjugated bile acids;
bilirubin monoglucuronide, but not unconjugated bilirubin; thyroid
hormones, BSP, LTC4, steroid hormones such as aldosterone,
dexamethasone and cortisol; angiotensin-converting enzyme
inhibitors (enalapril, temocaprilat), pravastatin, the magnetic
resonance imaging contrast agent gadoxetate
Oatp1a4, Oatp2
(Slco1a4; Slc21a5) Organic
anion transporting protein
Multispecific organic anion transporter for
Na+-independent uptake of bile acids and
other organic anions with predominant location
in pericentral hepatocytes; less important for bile
acid uptake than Oatp1a1
Similar to Oatp1a1: Conjugated and unconjugated bile acids;
high-affinity transport of digoxin; bilirubin monoglucuronide
(note that BSP and LTC4 are no substrates)
Oatp1b2, Oatp4 (formerly Lst-1)
(Slco1b2; Slc21a10) Organic
anion transporting protein
Multispecific organic anion transporter for
Multispecific organic anion transporter for
Na+-independent uptake of bile acids and a broad
range of other organic anions; Oatp1b2 is the full-length
isoform of rat liver specific transporter 1 (Lst-1)
Bile acids, DHEAS, LCT4; prostaglandin E2, BSP; estrogen
conjugates, thyroid hormones, cholecystokinin, gadoxetate, toxins
(e.g., microcystin)
MRP3/Mrp3 (ABCC3/Abcc3)
Multidrug resistance-associated
protein
ATP-dependent efflux of biliary constituents;
potential implications for removal of accumulating
bile acids in cholestasis
Divalent bile acids (e.g., sulfo-TLCA, sulfo-TCDCA), monovalent
bile acids; methotrexate, acetaminophen glucoronide, E217G, several
other glucuronides and glutathione conjungates of endogenous and
exogenous compounds
MRP4/Mrp4 (ABCC4/Abcc4)
Multidrug resistance-associated
protein
ATP-dependent cotransport of GSH and divalent
bile acids into portal blood; potential implications
for removal of accumulating bile acids in cholestasis
Divalent sulfated and monovalent bile acids; estrogen sulfates,
DHEAS, cyclic nucleotides, methotrexate
OSTα/OSTβ Organic solute
carrier
Na+-independent bile salt transport system; expressed
in hepatocytes, basolateral counterpart of apical
Asbt in intestine and kidney
Bile acids, digoxin, DHEAS, estrone 3-sulfate, prostaglandin E2
Canalicular membrane
BSEP/Bsep formerly SPGP/Spgp
(ABCB11/Abcb11) Bile salt
export pump
ATP-dependent transport of monovalent bile acids
into bile; major determinant of bile salt dependent
bile flow
Monovalent and divalent bile acids; low affinity for certain drugs
(taxol, vinblastine, pravastatin)
MRP2/Mrp2 (ABCC2/Abcc2;
cMOAT) Multidrug resistance-
associated protein
ATP-dependent transport of organic anions into bile;
major determinant of bile salt independent bile
flow by GSH transport
Divalent bile acids, but not monovalent bile acids; GSH, bilirubin
mono/diglucuronide, LTC4, several other organic anions most of
which are divalent amphipathic conjugates with glutathione,
glucuronate and sulfate
MDR1/Mdr1a/1b
(ABCB1/Abcb1) Multidrug
resistance- protein
Bile excretion of bulky organic cations; important
role in drug resistance
Multiple organic cations and other hydrophobic compounds
and hydrogen bond acceptors including protoporphyrin
and several drugs
MDR3/Mdr2 (ABCB4/Abcb4)
Multidrug resistance-protein
Phospholipid flippase, which mediates the
translocation of phosphatidylcholine from the
inner to the outer leaflet of the canalicular membrane
Phosphatidylcholine, porphyrins, digoxin, paclitaxel, vinblastine
FIC1/Fic1 (ATP8B1/ATP8b1)
familiar intrahepatic cholestasis
1 protein
ATP-dependent aminophospholipid translocase;
function not yet defined; Mutations cause PFIC1
and BRIC1
Unclear, possibly (hydrophobic) bile acids
(continued on next page)
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Table 1 (continued)
Gene Function Substrates
ABCG5/8/Abcg5/8 “Two-half transporters”, which mediate the sterol
and cholesterol transport into bile; mutations
cause sitosterolemia
Sitosterol, cholesterol
BCRP/Bcrp (ABCG2/Abcg2)
Breast cancer related protein
Mediates cellular extrusion of sulphated conjugates Sulfoconjugated organic anions such as estrone
3-sulfate, E217G, folic acid, protopophyrine IX,
methotrexate
AE2/Ae2 (SLC4A2)
Anion exchanger 2
Mediates bicarbonate transport into bile in exchange
for Cl− and contributes to bile salt independent bile flow
HCO3
−
Aquaporins (AQPs)
AQPs 0, 1, 4, 5, 8, 9 and 11
Integral membrane channel proteins that facilitate
rapid passive movement of water
Abbreviations used in this table: BSP, bromosulphthalein; CA, cholic acid; DHEAS, dehydroepiandrosteronsulfat; E217G, estradiol-17β-glucuronide; GCA, glyco-
cholic acid; GLCA, glyco-lithocholic acid; GSH, glutathione; LCA, lithocholic acid; LTC4, leukotriene C4; TCA, tauro-cholic acid; TCDCA, tauro-chenodeoxycholic
acid; TDCA, tauro-deoxycholic acid; TLCA, tauro-lithocholic acid; TUDCA, tauro-ursodeoxycholic acid; UDCA, ursodeoxycholic acid.
)
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remains to be determined [1,4]. Potential candidates for basolateral
bile salt efflux from enterocytes include t-Asbt (truncated Asbt,
which can function as an anion exchanger) identified in rat ileum,
the recently identified OST/Ostα-OST/Ostβ and Mrp3/MRP3,
which have both been identified in rat and human small intestine
[1,4,18].
Additional “cycles” include a cholehepatic cycle of bile acids
between bile duct epithelial cells (cholangiocytes) and hepato-
cytes, and reabsorption from proximal renal tubules preventing the
loss of glomerularly filtered bile acids into urine. Bile salts may
also undergo “cholehepatic shunting” from the bile duct lumen, via
cholangiocytes and the periductular capillary plexus. Bile salt
reabsorption by cholangiocytes is mediated by Isbt/ISBT, also
called Asbt/ASBT (SLC10A2) and may contribute in part to the
conservation of bile salts and the generation of a hypercholeretic
bile flow [1,4]. After uptake, bile salts are effluxed via the
basolateral membrane of cholangiocytes into the peribiliary plexus
by Mrp3/MR3, which has been identified in cholangiocytes and
gallbladder epithelium of rats and humans [1,4]. Although this
pathway probably plays a minor role under normal physiological
conditions, cholehepatic shunting of bile salts may become an
important escape route for bile salts under cholestatic conditions
when the bile duct epithelium proliferates. Under pathologic,
cholestatic conditions with disruption of the enterohepatic cir-
culation, these pathways may be “alternatively” used by biliary
compounds normally not excreted into urine. Bile formation not
only depends on the proper function of these transport systems, but
also on an intact cytoskeleton required for the movement of vesi-
cles and bile canalicular contractions, cell junctions that seal off the
bile canaliculi and maintain cell polarity, and signal transduction
cascades that regulate and coordinate these processes [1–5].
Cholestasis may result either from a functional defect in bile
formation at the level of the hepatocyte or from an impairment in
bile secretion and flow at the bile duct level [2,3,19,20]. Reduced
expression and function of transport systems play an important
role in the pathogenesis of cholestasis. In addition to transporter
changes, other mechanisms such as altered cell polarity, dis-
ruption of cell-to-cell junctions and cytoskeletal changes may be
involved [2,4,19]. Transport defects may be hereditary due to
genetic defects or acquired as a result of cholestatic injury. While
transporter changes in hereditary cholestasis are primary, mostalterations in acquired cholestasis are secondary. Decreased ex-
pression of transport systems may at least in part explain the
impairment of transport function resulting in or maintaining cho-
lestasis [2–4,19–21]. However, not all of the encountered
changes in transporter expression are ‘pro-cholestatic’ and
‘negative’ from a teleological point of view. While some of
these alterations contribute to cholestasis, other changes may rep-
resent compensatory (‘anti-cholestatic’) defense recations which
provide alternative excretory routes for accumulating cholephiles
in cholestasis. Generally, cholestasis is associatedwith a disruption
of the normal enterohepatic and nephrohepatic circulation, with an
increased cholehepatic shunting (reabsorbing toxic, stagnant bile
acids from the obstructed ducts in post-canalicular forms of
cholestasis) and an increased basolateral efflux of biliary
compounds from liver followed by their renal elimination. These
transporter changesmay be assisted bymetabolic changes of phase
I and II enzyme systems (e.g., cytochrome P450 enzymes,
sulfotransferases, glucuronyltransferases) involved in the detoxi-
fication of bile acids and other biliary compounds which make
them less toxic and better substrates for alternative elimination
pathways. Therefore, the changes encountered in cholestasis rep-
resent a mixture of pro-cholestatic and anti-cholestatic/adaptive
alterations of transport and enzyme systems.
Rodent models of hereditary and acquired cholestasis have
proven very useful to study the role of transport systems in the
pathogenesis of cholestasis.Mdr2 (Abcb4) knockout mice develop
a sclerosing cholangitis as a result of toxic, phospholipid-deficient
bile which contains free, non-micellar bile acids [22,23]. Bsep
(Abcb11) knockout mice [24] develop a much milder cholestasis
than their human counterparts (PFIC 2) which may be due to
differences in bile acid composition and the existence of additional
canalicular bile salt transport systems in mice [24,25]. Most of our
knowledge on acquired alterations of transport systems during
cholestasis is based on experimental animal models which mimic
to some extent specific clinical conditions [2–4,19–21,26]. Ex-
amples include rodent models with administration of endotoxin
(experimental model for inflammatory cholestasis), ethinylestra-
diol (oral contraceptive-induced cholestasis/cholestasis of preg-
nancy), alpha-naphthylisocyanate (vanishing bile duct syndrome)
and common bile duct ligation (extrahepatic biliary obstruction)
[26]. Mdr2−/− may represent an excellent model to study the
pathophysiology of chronic cholangiopathies including PSC
Table 2
Nuclear receptors, ligands and target transporter genes
Nuclear receptor Ligands Target transporter gene
RXR (NR2B1) Retinoid X receptor 9-cis retinoic acid; rexinoids Obligate heterodimeric partner for class II NR,
multiple target genes;
RAR (NR1B1) Retinoic acid receptor Trans-retinoic acid Ntcp, Mrp2, ASBT, Mrp3/MRP3
FXR (NR1H4) Farnesoid X receptor Hydrophobic bile acids such as CDCA,
DCA, CA, LCA, GW4064
Bsep/BSEP, Mrp2/MRP2; OATP1B1, OATP1B3,
I-BABP, Ostα/β, OSTα/β, Asbt, Mdr2/MDR3
(also: Shp/SHP)
SHP (NR0B2) Short heterodimer partner 1 None, transcriptionally activated by FXR Ntcp ,OATP1B1
PXR/SXR (NR1I2) Pregnane
(Steroid) X receptor
LCA and metabolites, DCA, CA , UDCA?,
rifampicin (human), PCN (rodent),
hyperforin, dexamethasone, statins
Mrp2/MRP2, Mrp3/MRP3, Oatp2, MDR1 (also:
phase / and II enzymes, e.g., Cyp3a/CYP3A, Sult2a)
CAR (NR1I3) Constitutive androstane receptor Androstenol (antagonist), phenobarbital,
TCPOBOP, bilirubin
Mrp2/MRP2, Mrp3/MRP3, Mrp4/MRP4, (also: phase /
and II enzymes, e.g., Cyp2b/CYP2B, Sult2a, Ugt1a1/UGT1A1)
VDR (NR1I1) Vitamin D receptor Vitamin D, LCA metabolites Asbt, Mrp3 (also: phase/and II enzymes, e.g., Cyp3a/CYP3A,
Sult2a/SULT2A)
LRH-1/FTF (NR5A2) Liver receptor homolog-1;
α1-fetoprotein transcription factor
None, bile acids and TNFα result in
upregulation of Lrh-1 mRNA
MRP3, Shp, Asbt
PPARα (NR1C1) Peroxisome proliferator
activator α
Fatty acids, statins, fibrates,
DHEAS, prostaglandins, etc.
Asbt/ASBT, Mdr2
LXR (NR1H3) Liver X receptor Oxysterols Abcg5/8/ABCG5/8
GR (NR3C1) Glucocorticoids ASBT, Ntcp/NTCP
HNF1α (TCF1) Hepatocyte nuclear factor
1 alpha
– Ntcp, Oatp1, Oatp2, Oatp4, Oatp1B1, Oatp1A3, Asbt
HNF3β (FOXA2) Hepatocyte nuclear factor
3 beta
– Ntcp, Mdr2
HNF4α (NR2A1) Hepatocyte nuclear factor
4 alpha
– Ntcp, Oatp1, Bsep, Mdr2 OATP1B1
Abbreviations used in this table: CA, cholic acid; DHEAS, dehydroepiandrosteronsulfat; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GW4064, specific
synthetic FXR ligand; LCA, lithocholic acid; PCN, pregnenolone-16α-carbonitrile; TCPOBOP, 1,4-bis-[2-(3,5-dichlorpyridyloxy)]benzene;UDCA, ursodeoxycholic acid.
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acid injection into the partially ligated bile duct may induce scle-
rosing cholangitis in rats as another animal model for PSC [28,29].
Several monogenetic, hereditary cholestatic syndromes such
as progressive familial intrahepatic cholestasis (PFIC), benign
recurrent intrahepatic cholestasis (BRIC), Dubin–Johnson
syndrome and liver involvement in cystic fibrosis now can
be attributed to specific mutations of individual hepatobiliary
transporter genes [30–32]. Mutations of the canalicular
transporters FIC1, BSEP and MDR3 account for the
phenotypic expression of PFIC-1, 2 and 3, respectively.
Functionally less significant mutations cause a more benign
phenotype and may be associated with BRIC 1 (FIC1) and 2
(BSEP) [33–35]. Hereditary MDR3 defects are also involved
in intrahepatic and gallbladder cholesterol gallstone formation
and the pathogenesis of cholestasis of pregnancy [30,31].
Reduced MDR3 levels have also been found in oriental
patients with intrahepatic bile duct stones, suggesting a role for
heterozygotes with MDR3 defects in the pathogenesis of this
syndrome. Dubin–Johnson Syndrome, a cause of hereditary
conjugated hyperbilirubinemia and defects in the excretion of a
variety of amphipathic organic anions, is caused by hereditary
MRP2 defects [31]. Sometimes hereditary and acquired factors
causing cholestasis can overlap, since incomplete or heterozy-
gous transport defects/mutations may predispose to acquired
cholestatic liver injury (e.g., subtypes of intrahepatic cholesta-
sis of pregnancy, drug-induced cholestasis) [31]. Acquired,
secondary downregulation of the nuclear bile acid receptor
FXR may contribute to cholestasis in PFIC1 (FIC1 disease)[36,37]. Transporter polymorphisms of the main hepatobiliary
export systems do not appear to play a major role in the
pathogenesis of PBC and PSC [38], although their role as
disease-modifier genes remains to be elucidated.
In daily clinical practice, acquired forms of cholestasis are
more relevant. Clinically, bland (e.g., drug or hormone-induced)
versus inflammatory hepatocellular cholestasis must be distin-
guished from vanishing bile duct syndromes involving
microscopic small interlobular bile ducts (e.g., primary biliary
cirrhosis, PBC) and biliary obstruction at the level of large,
macroscopically visible ducts (e.g., primary sclerosing cholan-
gitis, PSC). Generally, the acquired changes in transporter
expression in human cholestatic liver diseases are consistent
with concepts derived from the findings in experimental animal
models of cholestasis [21,26]. Transcriptional mechanisms
appear to be less relevant in humans compared to rodents
[12,39]. For example, in contrast to the dramatic reduction of
Mrp2 mRNA levels in endotoxin-treated rats [40], MRP2
mRNA levels remained unchanged in humans, indicating
species differences in its regulation [12]. This is further
supported by reduced MRP2 protein but unchanged MRP2
mRNA in the duodenum of patients with obstructive cholestasis
and findings obtained with endotoxin- and cytokine-challenged
human liver slices [41,42].
In addition to transporter changes, changes in membrane
fluidity, ultrastructural changes of the cytoskeleton and tethering
proteins (e.g., radixin), cellular (tight) junctions, and alterations
of cell signalling (e.g., protein kinase C), may also contribute to
hepatocellular cholestasis [2,5,43,44].
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Hepatobiliary transport systems are intensively regulated at a
transcriptional and posttranscriptional level to meet physiologic
demands and variations. Liver-enriched transcriptions factors
(e.g., hepatocyte nuclear factors, HNF) and nuclear (orphan)
receptors (NR) play a key role in the transcriptional regulation of
hepatobiliary transport systems [1,4,5,45] (Table 2). Members of
the HNF family are important for constitutive gene expression,
while nuclear (orphan) receptors rather represent inducers of gene
expression responsible for gene regulation in response to bile acid
accumulation or certain xenosensors. Binding of biliary consti-
tuents (e.g., bile acids, bilirubin), lipid products (e.g., oxysterols)
and xenobiotics (e.g., drugs) to NR facilitate the positive feed-
forward and negative feed-back regulation of hepatic transport
and phase I/II metabolism of these compounds under physiolog-
ical and pathological conditions [45].
Many alterations in bile acid transport and metabolism in
cholestasis can now be interpreted as NR-mediated action
since biliary compounds retained during cholestasis can act as
NR ligands and would be predicted to alter expression of res-
pective target genes encoding for transporters and enzymes
[1,4,5,45]. Depending on the cause of cholestasis, effects of
cytokines, bile acids, hormones or drugs may dominate the
picture. However, the extrapolation of physiologic or in vitro
NR effects to pathologic (e.g., cholestatic) conditions is com-
plicated by the fact, that NR themselves undergo marked
changes in their expression and function during cholestasis and
inflammation (see below) [1,3,26]. Thus, the expression
patterns observed in cholestasis are the cumulative result of
direct alterations of NR by the injury (e.g., proinflammatoryFig. 1. General principles of transcriptional hepatic organic anion transporter regulati
partner and liver enriched transcription factors mediate the transcriptional regulation o
under positive feedback control of HNF4α is the common master regulator of baso
1b2)) bile acid uptake systems. HNF4α in turn may be under negative control of the b
the glucocorticoid receptor. Please note, species differences in Ntcp regulation (see tex
and, sharing a common response element with PXR and CAR alsoMrp2. PXR regula
basolateral Mrp3 and Mrp4. The RARα: RXRα heterodimer again positively regula
Mrp3. LRH-1 induces Mrp3 expression.cytokines) and accumulation of biliary constituents secondary
to cholestasis (e.g., bile acids, bilirubin). In addition to trans-
criptional transporter changes, posttranscriptional events (af-
fecting mRNA processing, steady-state mRNA stability,
translational efficacy) and/or posttranslational changes such
as impaired targeting and sorting, transporter redistribution,
enhanced transporter protein degradation (e.g., via lysosomal or
ubiquitin–proteasome pathway), direct protein modifications
(e.g., (de-) phosphorylation, (de-) glycosylation), changes in
membrane fluidity or cis-/trans-inhibition of transport systems
by cholestatic agents (e.g., drugs) can also play an important
role in the pathogenesis of cholestasis [1–5].
4. General principles of transcriptional hepatic organic
anion transporter regulation
The transcriptional regulation of hepatic organic anion trans-
porters comprises a complex interacting network of (ligand-acti-
vated) nuclear (orphan) receptors (FXR, PXR, VDR, CAR, RXR,
RAR, LRH-1, PPARα, Shp) as well as liver enriched hepatocyte
nuclear factors (HNF1, HNF3, HNF4) [1,45,46] (Table 2; Fig. 1).
Binding of nuclear receptor agonists or antagonists can directly
translate physiological and pathophysiological requirements into
alterations of gene expression [1,45,46]. These effects can be
additionally modulated by transcriptional and posttranscriptional
regulation of the transcription factor itself [47–51]. Release of co-
repressors and recruitment of distinct co-activators is another
critical step in mediating nuclear receptor function [52]. So far,
three nuclear receptors (NR), the farnesoid X receptor FXR
(NR1H4), the pregnane X receptor PXR (NR1I2) and the vitamin
D receptor VDR (NR1I1), have been shown to bind a distincton in rat liver. Class II nuclear receptors heterodimerizing with RXR as obligate
f hepatobiliary transporter systems. Hepatocyte nuclear factor HNF1α, which is
lateral Na+-dependent (Ntcp) and Na+-independent (Oatp1, 2, 4 (Oatp1a1, 1a4,
ile acid induced FXR-SHP pathway. Ntcp is also under direct control of Stat5 and
t for details). FXR positively regulates the canalicular bile acid transporters Bsep
tes basolateral Oatp2 (Oatp1a4) and potentiallyMrp3, while CAR regulates both
tes Ntcp, probably Oatp4 (Oatp1b2) and also Mrp2, while negatively regulating
289A. Geier et al. / Biochimica et Biophysica Acta 1773 (2007) 283–308spectrum of hydrophobic bile acids as ligands [53–58]. The con-
stitutive androstane receptor CAR (NR1I3) is activated by bilirubin
[59], but a role for bile acid sensing has been postulated [60]. All of
them belong to class II nuclear receptors, that typically form
heterodimerswith the retinoidX receptor alphaRXRα (NR2B1) in
order to mediate binding to distinct DNA response elements in
respective promoter regions defined by different canonical hexa-
mer sequences [61]. In addition, the liver X receptor alpha LXRα
(NR1H3) was reported to be activated by 6α-hydroxy bile acids, a
hydroxylation product formed by CYP3A4 [62].
The best defined nuclear receptor for bile acids, FXR, is
critically involved in regulation of genes whose products mediate
hepatocellular bile acid uptake via Na+-dependent (NTCP) and
Na+-independent (OATP2 (OATP1B1), OATP8 (OATP1B3) [63,
64] mechanisms, canalicular excretion of monovalent (BSEP)/
divalent bile acids (MRP2) and bilirubin (MRP2) and the rate
limiting step of bile acid formation (via CYP7A1). FXR is abun-
dantly expressed in tissues belonging to the enterohepatic circu-
lation (hepatocytes, cholangiocytes and enterocytes), the kidney
and adrenal cortex [65]. Moreover, this receptor is also expressed
in a variety of non classical bile acid target tissues such as vascu-
lature and vasuclare smooth muscle cells [66]. FXR is activated
by bile acids in the rank order of potency: chenodeoxycholic acid
(CDCA)>deoxycholic acid (DCA)=lithocholic acid (LCA)>
cholic acid (CA) [55]. However, more detailed studies have
demonstrated that only CDCA is a full FXR agonist, while DCA,
CA and ursodeoxycholic acid (UDCA) are partial FXR agonists
regulating target genes in a gene-selective manner [67]. LCA even
acts as a partial FXR antagonist in vitro [68].β-muricholic acid (β-
MCA), a hydrophilic bile acid species and predominant bile acid in
rodents has not been shown to activate FXR so far [55]. Results in
FXR−/−mice indicate thatBsep is a direct target of FXR sinceBsep
baseline expression levels as well as Bsep induction upon CA
feeding is diminished in this animal model [69]. The human and
rodent BSEP gene contain an inverted repeat (IR-1) element in
their promotor regions that directly bind to the FXR:RXR
heterodimer upon activation by bile acids, resulting in enhanced
transactivation of the BSEP gene [69–73]. Thereby FXR is able to
directly regulate hepatocellular bile acid homeostasis by inducing
BSEP, the main bile acid export pump. In contrast, LCA reduces
BSEP expression in cell culture via FXR antagonistic activity [68],
proving another explanation for the cholestatic effects of the toxic
LCA (for Review [74]). TheMRP2 promotor can also be directly
transactivated by FXR agonists through a unusual, common ER-
8 response element for FXR, PXR and CAR [72]. However,
FXR−/− did not show decreased Mrp2 baseline expression or
impaired induction after bile acid loading, supporting redundant
regulatory mechanism for this transporter [49,72,75]. The
phospholipid flippase MDR3 in the canalicular membrane of
hepatocytes and OATP8 (OATP1B3), involved in basolateral bile
acid uptake in human hepatocytes are also, directly transactivated
by FXR through IR-1 elements in their promoter regions [63,76].
Recently, the human OSTα and OSTβ genes were identified to be
transactivated by FXR [77].
In addition to these direct, positive regulatory FXR effects as an
inducer of gene expression, FXR indirectly negatively regulates
gene expression via induction of small heterodimer partner(SHP (NR1I0)) [69,78,79]. The human and rodent SHP pro-
motor regions contain FXR response elements [78]. SHP is a true
“orphan” receptor since it has no ligands. Moreover, SHP lacks a
DNA binding domain but still contains a receptor interacting and
repressor domain [80]. SHP mediates its repressive effects on
nuclear receptor-mediated transactivation either via competition
with coactivators or via heterodimerization with other nuclear
receptors thereby blocking their ability to activate transcription
[78,79,81]. Since the Ntcp promotor does not contain an FXR:
RXRα binding element, FXR-dependent repression of Ntcp by
bile acids is mediated indirectly, at least in part, via SHP. The rat
Ntcp promotor is activated by several positive regulating elements
including HNF-1α, the RARα:RXRα heterodimer as well as the
signal transducer and transactivator 5 (Stat 5) [82,83]. Stat5 me-
diates induction of rat Ntcp by prolactin and growth hormone
[82,84]. In addition, another liver enriched transcription factor,
the divergent homeobox gene Hex, was reported to transacti-
vate the rat Ntcp promotor via a response element located in the
upstream region of the minimal promotor [85]. Bile acid-depen-
dent SHP induction has been shown to interfere with RXRα:
RARα activation of the Ntcp promoter, thus, reducing Ntcp
gene expression [86]. On the other hand, SHP also inhibits
HNF4α transactivation [81]. Considering the fact that HNF4
may positively regulate HNF1α [87], bile acid-induced FXR/
SHP-dependent downregulation of Ntcp could also be envisioned
by such a pathway. Recently, an HNF4 binding site in the rat Ntcp
promotor overlappingwith theRXRα:RARα response element has
been identified, indicating that SHP may also repress rat Ntcp via
reduced HNF4 activity [46,88]. However, HNF4, HNF1 and
RXRα:RARαwere previously shown to bind to and activate only
the rat minimal Ntcp promotor but not the human and murine
promoter [88] although recent evidence suggests a more distal
HNF4 element in both rodent promoters [89]. The only common
motif in all three species in the minimal promoter was HNF-3β,
suggesting that there might be relevant differences in regulating
the NTCP/Ntcp gene between species [88,90]. HNF3β might
have a negative regulatory function since HNF3β transgenicmice
have reduced Ntcp levels [91]. On the other hand HNF-3βmight
result in transactivation of Hex, which is predicted to stimulate rat
Ntcp expression [92]. To add more complexity, SHP has recently
also been shown to suppress the glucocorticoid receptor (GCR)-
mediated transactivation of the human NTCP promotor [46].
Reduced Ntcp mRNA levels after CA feeding in Shp−/− mice
indicate that additional Shp-independent pathways must exist
which mediate bile acid triggered downregulation of Ntcp [93].
Such potential pathways could include bile acid-induced, JNK-
dependent phosphorylation of RXRα leading to reduced DNA
binding of the RXRα:RARα heterodimer in the Ntcp promotor
[94,95]. On the other hand, activated c-Jun might also enhance
SHP transcription via an AP-1 binding site in the rodent and
human SHP promoter [94]. Moreover, SHP-independent repres-
sion of HNF4 by bile acids involving a yet unidentified posttrans-
criptional mechanism has also been described [88,96–98]. Bile
acids and FXR also negatively regulate OATP1B1, the main Na+-
independent bile acid uptake transporter in human. OATP1B1 is
suppressed by FXR involving a cascade including FXR-SHP
activation, SHP-HNF4 interaction and subsequent inhibition of
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OATP1B1 promotor contains a HNF1 binding site the regulatory
cascade may involve bile acid-dependent suppression of HNF1
via decreased activation of HNF4 by SHP dependent and/or
SHP independent mechanisms [98,99].
Findings in HNF1−/− and conditional HNF4−/− mice with
reduced Ntcp, Oatp1 (Oatp1a1) and Oatp2 (Oatp1a4) expression
[100,101] indicate a role of HNF1 and HNF4 as central positive
regulators of these basolateral bile acid uptake systems responsible
for constitutive gene expression. HNF1α also appears to be re-
quired for expression ofOatp4 (Oatp1b2) [99,102]. Moreover, the
genes encoding intestinal and renal Asbt, FXR (containing a
HNF1α binding site in its promoter [101]), and the intracellular bile
acid binding protein Akr1c2were found among the downregulated
genes in HNF1−/− mice underlining the central role of HNF1α in
bile acid homeostasis [101].WhileHNF1α is essential for the basal
constitutive promoter activity of ratNtcp, so far noHNF1α (as well
as HNF4α and RXR:RAR) binding sites have been identified in
the human minimalNTCP promotor [83,88]. However, the human
OATP2 gene contains an HNF1α binding site in its promotor
region [99]. Thus, HNF1α appears to be the master regulator of
basolateral Ntcp and Oatp expression. Of interest, HNF1α is also
able to negatively regulate its own expression and that of HNF4 by
a negative feedback loop [87]. HNF1α expression in turn depends
on HNF4α expression and is reduced under conditions of reduced/
HNF4α activity [98,103,104].
RAR together with its obligatory binding partner RXRα is at
least required for constitutive expression of rat Ntcp and binding
of this heterodimer to retinoid response elements in the pro-
motor regions of Ntcp as well as Mrp2 positively transactivates
these genes [83,105]. Recent reports suggest also a potential
positive transactivating role for RXRα:RARα in the promotor
regions of Oatp4 (Oatp1b2) [102] and indicate a negative
regulation of Mrp3 by RARα:RXRα binding [106]. The latter
finding would complement the proposed mechanism of Mrp3
upregulation via TNFα -induced liver receptor homologue-1,
LRH-1 (NR5A2) (also known as fetoprotein transcription fac-
tor, FTF) [107].
The classical hormone and xenobiotic receptor PXR is also
activated by bile acids such as LCA, 3-keto LCA and to lesser
extents byDCA and CA [56,58], thus implying a role for PXR not
only in xenobiotic defense mechanisms, but also in bile acid
metabolism and transporter regulation in addition to FXR. PXR is
highly expressed in liver and to lower extents in the intestine and
kidney [108] and also forms heterodimers with RXRα upon
ligand activation. A unique feature of PXR is its binding affinity
for a wide spectrum of diverse ligands and species differences
among ligand binding [109,110]. Thus a ligand which is a strong
activator of PXR in humanmay only be a weak activator of rodent
PXR, as examplified for rifampicin [111]. However, the DNA
binding domain is highly conserved [109]. Ligands of PXR
comprise several xenobiotics, including rifampicin, natural ste-
roids or hyperforin, the active compound of St. John's wort
[111,112]. The first bile acid transporter shown to be regulated by
PXR was Oatp2 (Oatp1a4) [56]. PXR−/− mice have reduced
baseline expression of Oatp2 (Oatp1a4) and lack induction upon
PXR stimulation via pregnenolone-16α carbonitrile (PCN).Ligand activated PXR was also shown to induce MRP3/Mrp3
expression in human cell lines and in vivo in mice, effects which
were not seen in the PXR−/−, implying a role for PXR also for
Mrp3 [113,114]. A complex regulation was demonstrated for
human as well as rodent MRP2/Mrp2, which contains an unusual
response element (ER-8) in its promoter, that can be transactivated
by either FXR, PXR or CAR [72]. Another link between FXR and
PXR is provided by the fact that human andmurine PXR is a target
for negative regulation of SHP [115]. Thus, it was shown that bile
acid-mediated induction of the FXR/SHP pathway mediates
repression of the classical PXR target CYP3A4/Cyp3a11 [115].
However, the impact of this pathway for transporter regulation has
not been evaluated so far. Moreover, a recent study has identified
PXR response elements in the promoter region of SHP in human
HepG2 cells [116].
The second xenobiotic nuclear receptor, CAR, which is abun-
dantly expressed in liver and intestine, again forms CAR:RXRα
heterodimers but can also bind as CARmonomer to phenobarbital
response enhancer modules (PREM) in CAR target genes [117].
Both, PXR and CAR predominantly function as inducers of gene
expression and represent so-called “xenosensors”. CAR also rec-
ognizes structurally diverse compounds and shares overlapping
xenobiotic ligands with PXR [112]. However, no binding and
activation of CAR by bile acids has directly been shown so far.
Interestingly, bilirubin is an activator of human and murine CAR
[59]. Similar to PXR, SHP also interacts indirectly with CAR via
recruitment of co-repressors or inhibition of co-activators and is
thus able to inhibit the transactivation of the classical CAR target
gene CYP2B [118]. In addition to the effects of CAR on MRP2/
Mrp2 (see above), an induction of human andmurineMRP4/Mrp4
was achieved by treatment with CAR activators [60,114]. This
induction was not found in CAR−/− mice. Mrp3 was upregulated
in rats and mice after treatment with various CAR activators
[114,119]. This role of CAR in mediating ligand-dependent in-
duction of Mrp3 was recently confirmed using CAR−/− mice
[120]. This study showed induction ofMrp3mRNAby lithocholic
acid (LCA) in wild-type but not in CAR−/− and PXR/CAR−/−,
while the induction ofMrp3wasmaintained in PXR−/−. Oatp2was
regulated inversely toMrp3 in these receptor knockouts, indicating
that CAR may play a major role in Mrp3 induction while PXR is
the major regulator of Oatp2. Bile acids might upregulate MRP3
also via LRH-1 since the human MRP3 promotor contains a
binding element for LRH-1 [121]. Since bile acids do not act as
LRH-1 ligands [122] another factor mediating bile acid-de-
pendent induction appears to be required [121]. TNFα may be
this factor since it upregulates LRH-1 expression in vitro and
in vivo [123].
VDR was recently shown to be the third nuclear receptor
activated by bile acids, almost exclusively by LCA and its deri-
vates [54]. While so far mainly bile acid detoxifying enzymes
such as Cyp3A4/Cyp3a11 and Sult2a1 have been shown to be
regulated by VDR, a recent report has identified a VDR response
element in the rat Asbt gene and its induction by calcitriol [106],
indicating that VDR may play also a role in bile acid transporter
regulation. Similar to anatagonizing effects of 9-cis retinoic acid
on FXR-induced BSEP expression [124], FXR-induced BSEP
expression was also inhibited by vitamin D [125].
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Cholestasis frequently occurs as a complication in patients
with sepsis and extrahepatic bacterial infections [126,127].
Endotoxin (also termed lipopolysaccharide, LPS) inhibits the
transport of organic anions at both the sinusoidal and canalicular
membrane of hepatocytes and affects both bile acid-dependent
and bile acid-independent fractions of bile flow [128–131].
LPS-induced proinflammatory cytokines include tumor necro-
sis factor α (TNFα), interleukin-1β (IL-1β) and interleukin-6
(IL-6), which are secreted by macrophages and Kupffer cells
shortly upon experimental LPS challenge [132,133], and have
been characterized as mediators of reduction in bile flow and
organic anion excretion [129,130]. The mechanisms by which
LPS-induced proinflammatory cytokines modulate transporter
gene expression at the transcriptional level have been
intensively studied over the past decade.
Experimental administration of LPS, TNFα, IL-1β or IL-6
reduces expression of several hepatocellular organic anion
transport systems at the basolateral or canalicular membrane
(Fig. 2). LPS leads to a rapid and marked downregulation of Ntcp
mRNA and protein expression to 10–30% in rats which occurs at
the transcriptional level as indicated by nuclear run-on studies
[134–137]. In human hepatoblastoma-derived HepG2 cells both
TNFα and IL-1β down-regulate NTCP promoter activity [105].
Similar effects on Ntcp mRNA expression have been observed in
mice early after application of either TNFα or IL-1β but not IL-6
[135]. In the pathophysiological context of inflammation-induced
cholestasis following LPS-treatment only IL-1β appears to be a
major regulator of Ntcp expression in vivo [137]. IL-6 as another
regulator of Ntcp gene expression only plays a crucial role in
downregulation during the later stages of endotoxemia [138]. InFig. 2. Transporter regulation in inflammation-induced cholestasis. Endotoxin-mediat
systems at the basolateral or canalicular membrane. Particularly IL-1b appears to be
conditions of endotoxemia in vivo. Downregulation of Ntcp expression is caused by d
RARa without induction of SHP. The function of the RXRa component is thereby af
JNK-dependent phosphorylation and a nucleo-cytoplasmic shift. Reduced HNF1a exp
Oatps 1, 2, and 4 (Oatp1a1, 1a4, 1b2) is at least in part mediated by reduced expressio
andMrp2 is mediated by a decreased expression of nuclear hormone receptors includ
1b-dependent regulator of the human MRP2 promoter.addition to Ntcp, a reduction of Oatps,Mrp2 and Bsep is observed
[40,102,137,139–143].
Downregulation of Ntcp gene expression during inflamma-
tion-induced cholestasis is caused by decreased binding activity
of the nuclear transcription factorsHNF1 andRXR:RAR to the rat
Ntcp gene promoter [83,105,134]. Alterations in the nuclear
availability and binding activity of the two critical transactivators
HNF1 and RXR:RAR are induced by the activation of in-
flammatory intracellular signalling cascades. The function of the
RXR:RAR complex during the acute phase response is decreased
by different posttranscriptional mechanisms affecting the RXR
component [47,95,144,145]. LPS and proinflammatory cytokines
including TNFα and IL-1β induce a rapid dose-dependent
decline in three distinct RXR mRNAs and proteins (RXR, RXR,
and RXR) in hamster liver within hours [47]. Increased RNA
degradation is primarily responsible for the repression of RXR,
because LPS only marginally reduces RXR transcription [47]. As
another mechanism nuclear RXR protein levels rapidly decrease
upon LPS, TNFα or IL-1β treatment of hamsters and mice
[47,145,146] due to a shift from the nucleus into the cytosolic
compartment [145]. In contrast to RXR, the subcellular localization
of its heterodimerization partner RAR remains unaffected by LPS
but its binding to the promoter is decreased by removal of the
heterodimeric partner [145]. LPS-induced stimulation of hepatic
Kupffer cells activates several intracellular stress pathways
including the mitogen-activated protein kinases, extracellular
signal-regulated kinase (ERK), c-Jun-N-terminal kinase (JNK)
and p38 mitogen-activated protein kinase (p38 MAPK) [147]. Of
those JNK has been shown to directly phosphorylate RXR
[95,148]. Inhibition of the JNK signalling pathway completely
prevents IL-1β-mediated suppression of RXR-dependent Ntcp
gene expression [95]. The parallel time course of JNK activationed signals reduce the expression of several hepatocellular organic anion transport
the major regulator of Ntcp and Mrp2 expression under the pathophysiological
ecreased binding activity of the nuclear transcription factors HNF1a and RXRa:
fected by different posttranscriptional mechanisms including RNA degradation,
ression may in turn be secondary to reduced HNF4a activity. Downregulation of
n and activity of their common regulator HNF1a. Transcriptional control of Bsep
ing FXR, PXR, and CAR. In addition, IRF 3 has recently been identified as a IL-
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LPS-induced activation of JNK results in phosphorylation and
possibly further posttranslational modification of RXR, triggering
its export from the nucleus to the cytosol [145].
As another major mechanism of Ntcp gene downregulation
during the acute phase response LPS has also been shown to
reduce HNF1 mRNA expression [103,149], nuclear protein
levels of HNF1 [149,150] and binding activity of HNF1
[102,134]. Similarly, decreased HNF1 binding activity in
mouse liver nuclei has been observed after TNFα or IL-1β
treatment [146]. In line with these findings clodronate-induced
depletion of Kupffer cells blocks cytokine-mediated Ntcp
suppression upon endotoxin exposure and the decreased binding
activity of RXR:RAR and HNF1 is preserved in clodronate/LPS
treated rats [151]. Reduced HNF1 expression may in turn be
secondary to reduced HNF4 activity [103,152]. Inflammatory
signals induced by LPS, particularly IL-1β, result in a
posttranscriptional reduction in HNF4 protein levels in HepG2
cells and rat livers probably caused by degradation via the
proteasomal pathway [103]. Recent data indicate that IL-1β
inhibits HNF4 promoter activity, protein expression, and its
binding to the chromatin via a JNK pathway [153]. In this study a
JNK-specific inhibitor blocked IL-1β-inhibition of HNF4
expression and JNK1 was able to phosphorylate HNF4 thereby
reducing its DNA binding. However, IL-1β could also affect
HNF1-mediated gene transcription in vivo during endotoxemia
by interference with chromatin remodeling facilitated by the
histone acetyltransferase activity of HNF1 coactivator proteins
such as steroid receptor coactivator (SRC)-1 and CREB-binding
protein (CBP)/p300 [137,154]. A recent study in the endotoxe-
mic mouse heart demonstrated a decreased expression of SRC-1
and CBP/p300 during the acute phase response [155]. The role
of these transcriptional cofactors in mediating gene-specific
effects of individual nuclear transcription factors is becoming
increasingly recognized [46].
The role for SHP in inflammation-mediated hepatic trans-
porter gene regulation remains controversial [94,105,156]. In
contrast to bile-duct ligation, studies in LPS-treated mice
demonstrate that LPS-induced cytokines reduceNtcp expression
without inducing SHP [156]. In line with these findings, LPS-
treatment even decreased SHPmRNA expression in mouse liver
[50]. Similarly cytokine-inactivation in obstructive cholestasis
rather increases SHP mRNA expression in vivo pointing
towards a role for cytokines as SHP suppressors [157]. However,
in vitro studies in primary rat hepatocytes have also demon-
strated the possibility of c-Jun/AP-1-mediated activation of the
SHP promoter via the JNK1-pathway which in turn suppressed
cholesterol 7-hydroxylase expression [94].
Expression of the organic anion transporters Oatp1, 2, and 4
(Oatp1a1, 1a4, 1b2) is uniformly decreased in endotoxemia at both
mRNA and protein levels [102,137,139–142]. Downregulation of
Oatp1 (Oatp1a1) and Oatp2 (Oatp1a4) is also mediated by in-
jection of inflammatory cytokines such as TNFα, IL-1β and IL-6
[138,140]. However, cytokine-inactivation studies in endotoxemic
rats indicate that downregulation of the basolateral transporters
Oatp1 (Oatp1a1) and Oatp2 (Oatp1a4) does not depend on single
cytokines alone and may involve both TNFα- and IL-1β-independent signal transduction pathways [137]. In line with this
finding recent data show that reducedOatp4 (Oatp1b2) expression
during LPS-induced cholestasis occurs through toll-like receptor 4
signals independent of inflammatory cytokines such as TNFα, IL-
1β or IL-6 [142,158]. The role of toll-like receptor 4 signals in the
regulation of organic anion transporters remains to be studied in
more detail. Downregulation of Oatps 1, 2, and 4 (Oatp1a1, 1a4,
1b2) during the acute phase response is at least in part mediated by
reduced expression and activity of their common regulator HNF1
[102,103, 149,150]. In addition to reduced HNF1 activity,
decreased expression of the inducers PXR and CAR during the
acute phase response might play a role in the downregulation of
Oatp2 (Oatp1a4) [56,58]. As described for RXR:RAR-mediated
Ntcp expression, posttranscriptional regulation of RXR during the
acute phase response by phosphorylation and nuclear export also
represents the common denominator for a coordinated down-
regulation of other nuclear receptor heterodimer target genes
[95,145]. LPS also leads to a marked reduction in PXR and CAR
mRNA expression, representing another regulatory component
[48,144, 159]. Similarly, IL-1β and IL-6 are able to suppress PXR
and CAR mRNA [160,161]. Recently, endotoxin and IL-1β in
particular have been shown to inhibit CAR-induced Oatp2 gene
expression via induction of nuclear factor (NF) B, which interferes
with the enhancer function of the distal glucocorticoid response
element in theCAR promoter [162]. In regard to downregulation of
Oatp4, decreased binding activities of several liver-enriched
transcription factors including HNF1, RXR:RAR, C/EBP and
HNF3, which bind to responsive elements in the proximal
promoter region, contribute to a reduction of gene expression
[102]. Besides the discussed reduction of HNF1 and HNF4
expression, LPS is also known to suppressHNF3 expression either
in cell culture or rat liver [163,164] although the relevance of these
findings for transporter regulation remains to be determined.
Reduced expression of human NTCP and OATP2 (OATP1B1)
have been observed in liver biopsies from patients with
inflammation-induced cholestasis [39], but the underlying tran-
scriptional mechanisms in humans remain to be determined.
Reduced canalicular secretion of bile acids and other organic
anions during endotoxemia is caused by a concomitant reduction
of the canalicular export pumps Bsep and Mrp2 [40,143]. While
BsepmRNA and protein expression is onlymoderately decreased
in inflammation-induced cholestasis upon LPS-treatment by 30%
[143], Mrp2 expression is more profoundly reduced to levels as
low as 10% of controls [40,136,137,165]. In contrast to TNF, only
IL-1β mediates suppression of human and rat MRP2/Mrp2
promoter activity in HepG2 cells [105,166]. Similarly, IL-1β
appears to be the major regulator of Mrp2 expression under the
pathophysiological conditions of endotoxemia in vivo because
respective anti-cytokine-pretreatment leads to a full preservation
of transporter expression [137]. In contrast to the transcriptional
downregulation of Bsep and Mrp2 found in LPS-treated rodents
in vivo and rat liver slices in vitro, posttranscriptionalmechanisms
play a more prominent role in the regulation of both human
transporter genes. In LPS-treated human liver slices BSEP and
MRP2 mRNA levels are unaltered whereas both proteins are
virtually absent under these conditions [42]. Similarly, profound
reductions in canalicular BSEP and MRP2 staining have been
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induced cholestasis [39]. Transporter retrieval from the canalic-
ular membrane has been described as another posttranscriptional
mechanism of early and reversible regulation of rodent Mrp2
during endotoxemia [167]. Transcriptional control of the Bsep
and Mrp2 genes is mediated by a group of nuclear hormone
receptors including FXR, RAR, PXR, and CAR [70–72,105]. As
described above in detail, phosphorylation and nuclear export of
RXR represents one component of the uniformly decreased
transporter gene expression during LPS-induced cholestasis
[95,145]. Furthermore, LPS-induced downregulation of Bsep
mRNA may be mediated by a suppression of FXR mRNA
[50,144]. Either LPS, TNFα or IL-1β significantly decrease FXR
mRNA expression and binding activity to the IR-1 response
element located in both human and rodent BSEP/Bsep promoters
[50,70,71].
In addition to reduced FXR- and retinoid-transactivation,
decreased activity of PXR and CAR may be important for
Mrp2 repression [48,50,105,123,144,159]. However, cytokine-
inactivation experiments in endotoxemic rats which show a fully
preserved Mrp2 expression upon anti-IL-1-treatment despite
continuously reduced binding to the Mrp2 promoter ER-
8 element and decreased nuclear protein levels of RXR, PXR
and CAR raise the question of additional, yet unknown
regulators [137]. One IL-1β-dependent regulator has recently
identified for the human MRP2 gene: IL-1β induces down-
regulation of the MRP2 gene by inactivating interferon
regulatory factor (IRF) 3 binding to an interferon stimulatory
response element (ISRE) in the human promoter sequence [168].
Much less is known about the regulation of the basolateral
overflow systems Mrp3 and Mrp4 during inflammatory chole-
stasis and the limited findings are still contradictory. Either endo-
toxin or TNF treatment induces a decrease of Mrp3 mRNAFig. 3. Transporter regulation in estradiol-induced cholestasis and pregnancy. Several
been identified as an important modifier. Ntcp expression is profoundly downregulat
basal expression of Ntcp in part by interfering with the upregulating effect of prolacti
Furthermore, estradiol-mediated induction of the nuclear receptor SHP might contri
promoter. Apart from Oatp4 (Oatp1b2), all basolateral anion transporters are transc
Reduction of Mrp2 and Bsep expression involve posttranscriptional (pt) mechanismexpression in mice [140,159] whereas induction of Mrp3 mRNA
is found in LPS-treated rats [169]. This difference in gene regu-
lation is not necessarily contradictory, but may rather reflect
species differences observed in inflammation-induced transcrip-
tional regulation. The latter finding is confirmed by in vitro
studies using HepG2 and HuH7 cells which demonstrate an
increased expression of Mrp3 mRNA after cytokine stimulation
[123,170]. Furthermore, TNFα increases binding of the transac-
tivator LRH-1 to theMrp3 promoter and a subsequent increase in
reporter activity [123]. Indirect evidence for a Mrp3 expression
stimulating effect of TNFα in vivo is also derived from obser-
vations in TNFR-knockout mice during long-term bile duct ob-
struction [123]. Regulation of the second rescue transporter Mrp4
in endotoxinemia still needs to be determined.
6. Transporter regulation in estradiol induced cholestasis
and pregnancy
Pregnancy is associated with significant qualitative and
quantitative hormonal changes. Elevated plasma concentrations
of estrogens and progesterone contribute to considerable changes
in basal expression and regulation of transporters (Fig. 3). Several
transport proteins are differentially expressed between genders,
and estradiol has been identified as an important modifier. The
different concentrations of estradiol between genders are respon-
sible for the significantly reduced basal expression of Ntcp in
female rats [171,172]. It is straightforward to hypothesize that
pregnancy-associated changes may have a similar mechanism.
During experimental estradiol-induced cholestasis in rats
reduced basolateral Ntcp expression parallels Na+-dependent
uptake of bile acids [173]. Although estradiol reduces basal
expression of Ntcp in rats, Cao et al. observed no changes in Ntcp
expression during pregnancywhile finding a significant inductiontransport proteins are differentially expressed between genders, and estradiol has
ed, while expression of all Oatps is only moderately affected. Estradiol reduces
n on Stat5 binding to the Ntcp promoter via a signalling cascade involving ERa.
bute to the decreased binding activity of HNF1a and RXRa:RARa to the Ntcp
riptionally downregulated, presumably via reduced activity of HNF1a or PXR.
s since mRNA levels remain stable after estradiol and throughout pregnancy.
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postpartum [174]. This upregulation could be causally linked to
prolactin secretion and subsequent binding of Stat5 to the Ntcp
promoter [84,175]. Placental lactogen secretion during pregnancy
should also elevate Ntcp expression, but the absence of
expression changes during pregnancy despite the estradiol and
prolactin effects led to the hypothesis that one effect abrogates the
other. Subsequently the same group could show that estradiol
represses the prolactin effect during pregnancy via a signalling
cascade involving ER and Stat5 [176]. Another group demon-
strated downregulation of Ntcp in pregnant rats and also found
upregulation of Stat5, but downregulation ofHNF1 and decreased
promoter binding of RXR:RAR as initiating elements, indicating
complex transcriptional events [177]. Ethinylestradiol (EE)-
mediated induction of the nuclear receptor SHP might either
directly or indirectly contribute to the decreased binding activity
ofHNF1 andRXR:RAR to theNtcp promoter [178].WhileOatp1
(Oatp1a1) remains unchanged in pregnancy and shows no gender
difference, Oatp2 (Oatp1a4) is slightly (and not significantly)
decreased on protein and mRNA level [172,174,179]. Interest-
ingly, it has been shown that after treatment with EE protein
expression of all Oatps (1, 2 and 4) (Oatp1a1, 1a4, 1b2) is
moderately reduced in rat liver, while Ntcp protein expression is
severely downregulated [173,179]. This expression pattern might
contribute to a maintained Na+-independent bile salt uptake in
EE-treated rats [173]. Apart fromOatp4 (Oatp1b2), all basolateral
anion transporters were transcriptionally repressed, presumably
via HNF1, C/EBP or PXR [179]. This corresponds to results from
the estradiol studies and suggests that antagonistic mechanisms in
regulation during pregnancy may be valid not only for Ntcp. One
such potential antagonistic mechanism could be the estrogen
activation of the nuclear receptor CAR [180].
Although basal expression of canalicular Mrp2 does not differ
between genders in rodents [181,182], hepatic Mrp2 protein
expression is reduced in rat liver to about 50% of control animals
during pregnancy [183]. This reduction of protein mass is
accompanied by a decrease of Mrp2 function as measured by
biliary excretion of the classic Mrp2 substrate 2,4-dinitrophenyl-
glutathione [183]. Interestingly this appears to involve posttran-
scriptional mechanisms since Mrp2 mRNA remains stable
throughout pregnancy [174]. Comparable changes in Mrp2 ex-
pression are also observed after experimental EE treatment in rats
where protein levels are decreased to 50% without corresponding
changes in mRNA levels [40,143]. As described in other models
of cholestasis, estradiol-17β-glucuronide induces endocytosis of
Mrp2 from the canalicular membrane [184].
For rat Bsep, in vitro studies support a role of -estradiol in
transcriptional downregulation of this gene [185]. One could
speculate that estradiol-induced Bsep repression is mediated by
reduced FXR binding [67]. Consequently it was demonstrated that
after administration of EE Bsep protein expression decreased
significantly to about 60% [143], an effect that was reversible by
administration of ursodeoxycholate (UDCA) [186]. In contrast,
reduction of Bsep-mediated bile acid-dependent bile flow after
estradiol-17-glucuronide administration does not primarily repre-
sent a gene regulation event but is mechanistically linked toMrp2-
mediated transport of estradiol-17-glucuronide into bile [187,188].Mrp3 is considered one of the basolateral “overflow”-pumps
compensating for impaired canalicular Mrp2. Of note, Mrp3 is
downregulated to about 50% of the control expression during
pregnancy on protein level, i.e. to the very same extent as Mrp2
[183]. However, Mrp3 mRNA is also downregulated to 50% of
normal controls in contrast to unchanged Mrp2 mRNA [183], so
that pregnancy cannot be compared to the cholestatic conditions
with compensatory induction of basolateral efflux pumps. Effects
of pregnancy or experimental estradiol application on Mrp4 ex-
pression have not been investigated in detail so far. Studies in mice
did not show any changes in Mrp4 expression in contrast to the
marked changes of Mrp2 and Mrp3 in pregnancy [189]. In addi-
tion, a significant increase of renal Mrp3 and a pronounced down-
regulation of renal Mrp4 are observed in these pregnant mice,
although, the impact of these findings need to be further in-
vestigated [189]. Similar to the higher expression of bile acid
sulfotransferases in female mice [190] also sulfated bile acid-
transporting Mrp4 was higher expressed in livers of female mice
[189].
7. Transporter regulation in obstructive cholestasis
Obstructive cholestasis induced by CBDL initiates
marked changes in transporter expression in rat liver (Fig. 4).
As an important protective regulatory step, the basolateral
Na+-dependent bile acid uptake system, Ntcp, is down-
regulated to prevent further bile acid uptake by hepatocytes
[191–193]. While Oatp1 (Oatp1a1) is also decreased during
obstructive cholestasis, maintained Oatp2 (Oatp1a4) and
Oatp4 (Oatp1b2) expression ensures continuos elimination
of other organic anions into the bile under these conditions
and contributes to the progressive nature of obstructive liver
damage [192,194,195]. Most prominent is the downregula-
tion of rat Mrp2 to less than 10% of the normal expression
after 7 days of CBDL [40]. However, this downregulation does not
only prevent biliary excretion of the endogenous substrate
bilirubin diglucuronide but also of many exogenous and
potentially toxic Mrp2 substrates which can accumulate in the
liver. Accumulation of such compounds can decrease glucuroni-
dation in hepatocytes and therefore inhibit metabolism and detoxi-
fication [41]. Alternatively, these compounds are effluxed into the
sinusoidal blood via basolateral transport systems which are com-
pensatively upregulated (Mrp3 and 4) [8,11,192]. This also com-
prises bile acids, especially in their metabolized (glucuronidated
and sulfated) form, followed by their renal excretion. Interestingly,
Mrp2 downregulation during obstructive cholestasis is absent in
mice indicating fundamental species differences [196]. Bsep as
canalicular bile acid exporter is largely maintained during ob-
structive cholestasis [143].
It is noteworthy that the mechanisms of Ntcp downregulation
during obstructive cholestasis are completely different from in-
flammatory states (such as endotoxin-related cholestasis [137].
Systemic proinflammatory cytokines have no effect on Ntcp ex-
pression during obstructive cholestasis [157]. Selective inactivation
of TNFα and IL-1β is without effects on Ntcp expression, clearly
demonstrating that downregulation of Ntcp in obstructive
cholestasis is independent of these cytokines. Rather, accumulation
Fig. 4. Transporter regulation in obstructive cholestasis. Obstructive cholestasis induces a marked downregulation of basolateral Ntcp andOatp1 (Oatp1a1) expression
as an important protective regulation step to prevent further bile acid uptake, while maintainedOatp2 and 4 (Oatp1a4, 1b2) expression ensures continuos elimination of
other organic anions into the bile. Most prominent is the downregulation of canalicularMrp2whereas Bsep expression is relatively well preserved. Basolateral overflow
systems including Mrp3 and 4 are compensatorely upregulated during biliary obstruction. Mechanisms of Ntcp downregulation during the early stage of obstructive
cholestasis in vivo are completely different from inflammatory states since downregulation is mediated without major contribution of cytokines by accumulating bile
acids per se. Such effects may involve bile acid-dependent suppression of the HNF4α/HNF1α pathway by SHP-dependent and independent mechanisms. In contrast IL-
1b leads to decreased binding of the RXRa:RARa heterodimer to theMrp2 promoter. Reduced binding activity of the Y-box binding protein YB-1 may have additional
suppressive effect on Mrp2 expression. During the early obstructive phase a rapid posttranscriptional mechanism adds to Mrp2 downregulation. The mechanism of
upregulation of Mrp3 and 4 has not yet been fully elucidated. Bilirubin induces Mrp3 expression likely by stimulating CAR and may contribute as a regulator during
obstructive cholestasis. In addition biliary obstruction leads to enhanced binding of theMrp3 transactivator Lrh-1 in a TNF-dependent fashion and decreases the activity
of RXRa:RARawhich functions as a repressor ofMrp3. Hypothetical mechanisms ofMrp4 induction include upregulation via the xenosensors CAR and PXR that have
been shown to be activated by bile acids and bilirubin. Recently the transcription factor Nrf2 has been suggested that is another regulator of basolateral Mrp expression.
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downregulateNtcp [156,157,197]. Alternatively, it has been shown
in vitro that bile acids are also capable of inducing SHP via an
FXR-independent mechanism: taurocholic acid strongly activates
JNK and overexpression of c-Jun in turn results in enhanced SHP
promoter activity [94] which, in the light of above cited data, may
contribute toNtcp repression during obstructive cholestasis. During
the first 3 days of CBDL, SHP mRNA expression correlates in-
versely with Ntcp expression while after 7 days SHPmRNA levels
approximate normal values while Ntcp remains repressed [156].
This apparent discrepancy could be attributed to rising levels of
proinflammatory cytokines such as TNFα and IL-1β over time
[197], since these cytokines are known to inhibit RXRα:RARα
activity which is decreased primarily during later stages of biliary
obstruction [41,95,105,198].Moreover, bile acids have been shown
to suppressHNF4α transcription through SHP-independent mech-
anisms [96,98], effects which could explain reduction of HNF1α
and subsequent Ntcp expression despite low SHP levels. Taken
together bile acids per se accumulating during the early stage of
obstructive cholestasis without major contribution of cytokines are
the dominant cause for Ntcp downregulation after CBDL. Such
effects may involve bile acid-dependent suppression of the
HNF4α/HNF1α pathway by SHP-dependent and independent
mechanisms [98] as a central pathway of Ntcp gene regulation.
Downregulation of Oatp1 could also be explained via reduced
HNF1 [101].
One of the central regulatory elements during obstructive
cholestasis is again RXRa. Obstructive cholestasis induces secre-
tion of IL-1β and leads to decreased binding of the RXRa:RARaheterodimer to the Mrp2 promoter thereby reducing transcription
of the rat Mrp2 gene [105,198]. Although so far only shown for
inflammation-induced cholestasis (LPS model), it is likely that
also in obstructive cholestasis which is also accompanied by
systemic release of proinflammatory cytokines such as TNF and
IL-1 [199,200], a rapid decline of RXR levels in the nucleus may
play an important role, leaving the other receptors without partner
for dimerization [145]. Downregulation ofMrp2 via the systemic
proinflammatory cytokine IL-1β is also observed in the duodenum
[41], but interestingly enough not in kidney [198]. This indicates
organ-specific regulatory mechanisms beyond the described
cascades. Moreover, binding activity of the Y-box binding protein
YB-1 is enhanced in obstructive cholestasis and may have addi-
tional suppressive effect on Mrp2 expression [201]. Downreg-
ulation of Mrp2 protein expression is much faster than of Mrp2
mRNA expression in liver and intestine [41,198]. This may in-
dicate a rapid posttranscriptional mechanism for Mrp2 downreg-
ulation in the early phase after CBDL (up to 3 days), while the
transcriptional effect requires more time. The posttranscriptional
mechanismsmay comprise translational regulation [202] aswell as
mechanisms for reducing the half life of the protein, e.g., by
removal from the canalicular membrane [203].
Bsep expression during obstructive cholestasis is relatively
well preserved compared with other membrane transporters and
may lessen the extent of liver injury produced by bile acid
retention particularly when cholestasis is prolonged [143]. In-
duction of Bsep by bile acids via FXR seems to operate as an
adaptive mechanism under these conditions by which accumu-
lating bile acids promote their own export into bile [10,69,204].
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the presence of a complete obstruction may aggravate cholestatic
liver injury (bile infarcts) in this situation [23].
Themechanism ofMrp3 and 4 induction has not yet been fully
elucidated. Administration of bilirubin alone (just referred to as
bilirubin without closer specifications) is sufficient to induce
Mrp3mRNA in Sprague–Dawley rats [192] likely by stimulating
CAR [59,114,120] and may also contribute during obstructive
cholestasis but obviously represents not the only mechanism for
upregulation. Released TNFα induces expression of LRH-1
during obstructive cholestasis, and enhanced LRH-1 binding to
the Mrp3 promoter was followed by upregulated expression of
mRNA and protein in cholestatic mice liver [123]. RXR:RAR
functions as a suppressor of human and rat MRP3/Mrp3
expression. Upregulation of MRP3/Mrp3 during obstructive
cholestasis occurs when RXR:RAR binding to a DR-2 element in
the promoter is diminished [106]. However, differences in Mrp3
regulation exist between species and even within different mouse
strains, since a higher basal expression Mrp3 is not further
induced in FVB/129 Ola mice after 3 days of bile duct ligation
[205]. PXR has also been implicated in upregulation of Mrp3 in
mouse liver and theoretically may be activated in obstructive
cholestasis by accumulating, hydrophobic bile acids [49,113].
Biliary obstruction induces a pronounced upregulation ofMrp4 in
mouse liver and kidney [10,189]while being downregulated in rat
kidney [11]. Upregulation ofMrp4 was even more pronounced in
FXR−/− [10] implying an FXR-independent mechanism. The
precise (probably species-dependent) mechanisms need to be
further studied. Hypothetical mechanisms include upregulation
via the xenosensors CAR and PXR that have been shown to be
activated by biliary compounds (e.g., bilirubin, bile acids)
[59,60,113]. Recently it was suggested that the transcription
factor NF-E2-related factor (Nrf2) may be a common regulator of
basolateral Mrp expression, since Nrf2−/− did not respond with
Mrp1,3,4 and 5 induction after BDL. This finding was
accompanied by marked reduction of bile serum acids in these
animals, consistent with their role in basolateral bile acid reflux in
cholestasis [206]. Lack of Ostβ – and to a lesser degree – Ostα
induction in FXR−/− mice undergoing BDL underline the
importance of bile acids and FXR in the regulation of Ostα/β [14].
Primary biliary cirrhosis (PBC) and primary sclerosing chola-
ngitis (PSC) represent the prototypic, chronic cholestatic liver
disease in humans. Downregulation of MRP2 was observed in
patients with chronic obstructive cholestatic caused by PSC [207].
This strengthens the data from a rat model for PSC, where a sharp
decline in Mrp2 protein expression was observed [29]. However,
Mrp2 expression is maintained in a mouse model of PSC, while
Ntcp and Oatp1 (Oatp1a1) are reduced in this model, suggesting
that downregulation of import systems may be the predominant
longstanding adaptive mechanism [14]. In analogy to the diverse
regulation ofOatps in experimental cholestasis,mRNA expression
of OATP-A (OATP1A2) is upregulated in PSC (in contrast to
downregulation of OATP2 (OATP1B1) [75]), which has been
interpreted as an attempt to facilitate efflux of cholephiles from
cholestatic hepatocytes into the sinusoidal blood [208]. Cholestasis
associated with PBC may have an “obstructive” component at the
small bile duct level as a result of ductopenia in advanced stages ofthe disease. In early stages, no differences were found in patients
compared to healthy controls [39]. With disease progression,
however, OATP2 (OATP1B1) and – to a lesser degree – NTCP
expression was downregulated in later PBC stages (III and IV),
while MRP3 and MDR P-glycoprotein expression was upregu-
lated [75]. Recent data indicate, that MRP4 and OSTα/β are also
induced in PBC [209]. Induction of basolateral MRP3, MRP4 and
OSTα/β together with downregulation of basolateral uptake
systems (NTCP, OATP2 (OATP1B1)) may at least in part explain
the appearance of bile acids and conjugated bilirubin in plasma and
the shift towards renal excretion. Teleologically these changesmay
be protective by limiting continuing bile acid overload of cho-
lestatic hepatocytes. Expression of canalicular BSEP and MRP2
even increases in PBC stage III before returning to normal levels in
stage IV [75]. Colabeling studies of BSEP and MRP2 with other
canalicular markers have revealed a normal canalicular localiza-
tion pattern on confocal laser scanning microscopy. However,
other studies have reported diminishedMRP2 expression by either
transcriptional [211] or posttranscriptional mechanisms [43]. Taken
together, the changes in hepatobiliary transporter expression in
PBC represent secondary, adaptive rather than primary, causative
changes in chronic cholestasis. Livers from PFIC patients also
showed secondary, adaptive transporter changes which were prin-
cipally comparable with PBC with the interesting exception of
MRP3 which was not induced in these livers [212]. Studies in
patients with biliary obstruction undergoing percutaneous transhe-
patic biliary drainage (PTBD) revealed a downregulation ofMRP2,
BSEP and induction of MRP3 [213]. NTCP mRNA levels were
also decreased in patients with extrahepatic biliary atresia and
subsequently increased if complete biliary drainage by portoenter-
ostomy (Kasai procedure) was achieved [214], while BSEP
expression was relatively well preserved, even in untreated patients
[215]. The transcriptional mechanisms underlying the adaptive
transporter changes remain to be determined in more detail, al-
though posttranscriptional effects (e.g., enhanced retrieval, deg-
radation)may bemore important in human cholestasis. Preliminary
data indicate reducedmRNA levels of FXR and its target gene SHP
in human inflammatory and obstructive cholestasis [216] as well as
in PFIC1 and 2 [217].
8. Transporter regulation during liver regeneration and
toxic liver injury
Liver regeneration occurs in response to various forms of
hepatocellular injury including viral hepatitis, toxic, or drug-
induced liver injury and surgical resection [218,219]. This
complex process results in restoration of the original liver mass
and maintenance of liver-specific functions but is frequently
associated with transient cholestasis. The underlying molecular
pathogenesis has been described in two distinct animal models
after either partial hepatectomy or toxic zone 3 liver injury
induced by carbon tetrachloride (CCl4) [137,220–223]. While
canalicular transporter expression is maintained, a coordinated
downregulation of basolateral transport systems might protect
replicating liver cells by diminishing the uptake of potentially
toxic bile salts, because the remaining liver initially cannot cope
with the original bile acid pool (Fig. 5).
Fig. 5. Transporter regulation during liver regeneration and toxic liver injury. Different forms of liver regeneration induce a coordinated downregulation of basolateral
transport systems while canalicular transporter expression is maintained. Toxic liver injury leads to a downregulation of HNF1a binding activity whereas RXRa:RARa
binding remains unaffected. TNFa represents the master regulatory cytokine for the HNF1a-dependent reduction of basolateral Ntcp, Oatp1 andOatp2 (Oatp1a1, 1a4)
expression during liver regeneration in vivo. The molecular mechanism responsible for Mrp3 induction after subtotal hepatectomy remains unclear since binding
activity of the repressor RXRa:RARa is not significantly altered during liver regeneration and the influence of TNFa signalling on the inducer LRH-1 is controversial.
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basolateral Ntcp is diminished to 25% and 50%, respectively
[220–222]. Likewise Oatp1 (Oatp1a1) and Oatp2 (Oatp1a4)
protein declines to 50% but reduction in mRNA expression is less
pronounced [221,222]. In contrast to reduced expression of
basolateral transporters, the canalicular export pumps Bsep and
Mrp2 remain stably expressed or even increased (maximum
increase of protein by 50–80%) 24 h after surgery [221,222].
Mrp3 expression remains stable after 70% hepatectomy but pro-
tein expression is increased after more extensive 90% resection
during the later time course after 72 h [224].
Similar changes in transporter expression have been observed
in the CCl4-model of toxic liver injury [137,223]. Reduced
mRNA expression of the basolateral uptake systems Ntcp, Oatp1
(Oatp1a1) and Oatp2 (Oatp1a4) were associated with decreased
transcriptional activities in nuclear run-on studies [223]. Down-
regulation of Ntcp mRNA was significantly correlated to
increased ALT levels [223]. Oatp4 (Oatp1b2) expression occurs
exclusively at the posttranscriptional level with reduced protein
expression in the presence of unchangedmRNA levels [223]. The
unchanged expression of the canalicular export pumps Bsep and
Mrp2 resembles the results after partial hepatectomy [223].
The molecular mechanisms underlying hepatocellular trans-
porter regulation have been studied in more detail only in toxic
liver injury [137,223]. As known for liver regeneration after
partial hepatectomyCCl4-toxic liver injury also leads to amassive
induction of TNFα necessary for priming of hepatocytes to enter
the regenerative cell cycle [223,225,226]. Cytokine-inactivation
studies in CCl4-treated rats clearly demonstrated that TNFα rather
than IL-1β represents the master regulatory cytokine for the
basolateral transporter gene expression during liver regeneration
[137]. In contrast to IL-1β, TNFα inactivation alone fully
prevents downregulation of Ntcp, Oatp1 (Oatp1a1) and Oatp2
(Oatp1a4) mRNA expression.Toxic liver injury leads to a downregulation of HNF1 and C/
EBP DNA binding activity whereas RXR:RAR binding remains
unaffected [223]. HNF1 activity can be maintained by anti-TNF
treatment whereas IL-1 inactivation exerts only partial effects
[137]. The coincidence of maintained basolateral transporter
expression in parallel to HNF1 activity in the light of an almost
absent expression of these transporters in HNF1 knockout mice
strongly favours a TNF-induced HNF1-mediated mechanism of
Ntcp, Oatp1 (Oatp1a1) and Oatp2 (Oatp1a4) repression [101,
137]. Unchanged nuclear levels of RXR, PXR and CAR byCCl4-
treatment and a suppressed binding activity to a DR-3 consensus
site despite cytokine inactivation indicate the possibility of post-
translational changes such as phosphorylation during toxic liver
injury but exclude these inducers asmediators ofOatp2 (Oatp1a4)
downregulation [137].
The hypothesis of TNFα as the central regulator of
transporter gene expression during liver regeneration is in line
with an unchanged Mrp2 expression after both partial
hepatectomy and toxic liver injury. In vitro experiments clearly
demonstrated that in contrast to IL-1β, TNFα is unable to affect
either Mrp2 promoter activity or nuclear levels of RXR:RAR
[105]. The molecular mechanism responsible for Mrp3
induction after subtotal hepatectomy remains still unclear.
Binding activity of the repressor RXR:RAR is not significantly
altered during liver regeneration and the influence of the TNF/c-
jun/AP-1 pathway on LRH-1, a Mrp3 inducer, is still
controversial [94,123]. Subsequent studies need to address
further details of an adaptive Mrp3 and Mrp4 response during
liver regeneration.
9. Potential therapeutic implications
The increasing information on the molecular mechanisms of
bile acid transport and metabolism under physiological and
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empiric treatment strategies (i.e. UDCA, rifampicin (Rifa),
Phenobarbital (PB)). More importantly, understanding thera-
peutic principles of “old” drugs may guide the development of
novel, more effective drugs for cholestatic liver diseases.
UDCA improves biochemical and clinical parameters in a
variety of human cholestatic syndromes and is considered the first
line treatment for PBC and PSC although the effects on survival
free of liver transplantation are controversial [227,228]. One
proposed mechanism of UDCA action at least in mice includes
stimulation of hepatocellular transport mechanism. In naïve mice,
UDCA stimulates the expression of canalicular efflux systems
(i.e. Mrp2, Bsep) [75,204] for “orthograde” biliary excretion and
adaptive basolateral export pumps (i.e. Mrp3, Mrp4) effluxing
bile acids back from hepatocytes into to sinusoidal blood [14,75].
Moreover, UDCA stimulates renal (Mrp2, Mrp4) and intestinal
(Mrp2, Mrp3) efflux pumps in mice, changes which may coor-
dinately result in increased elimination of potentially toxic biliary
constituents [75]. Recent human evidence demonstrates, that the
effects of UDCA on canalicular excretion (BSEP) and basolateral
alternative efflux (MRP4) are also seen in otherwise healthy non-
cholestatic gallstone patients [229]. UDCA enrichment correlated
positively with OATP2 (OATP1B1) and MRP2 in PBC patients
[75], effects which could at least in part contribute to reduced
bilirubin and bile acid levels observed in these patients [227,230].
In addition, UDCA has been shown to stimulate bile acid hydro-
xylating CYP3A4/Cyp3a11 in human and rodents [231,232] and
to downregulate the key enzyme of bile acid synthesis, CYP7A1,
at least in vitro [67,233]. Thus, UDCA appears to act on the
metabolic level by induction of detoxification pathways and on
transporter level by restoring defective transporters and generat-
ing alternative overflow-systems for accumulating biliary com-
pounds. AlthoughUDCAhas been the focus of research for many
years, no definite transcriptional target or nuclear receptor partnerFig. 6. Nuclear receptors as potential therapeutic targets in cholestatic disorders. FXR
reduction of Na+-dependent and the major Na+-independent transport systems, Ntcp
acid-dependent bile flow via induced Bsep and bile acid-independent bile flow via ind
agonists mainly stimulate Oatp2 (Oatp1a4), Mrp2 and potentially Mrp3. CAR agoni
accumulated bile acids, Mrp3 and Mrp4. Continuous lines and arrows, FXR effectsof UDCA has been characterized. So far there has been one report
suggesting that UDCA activates human PXR in vitro and induces
CYP3A4 [232] and another study suggesting that UDCA might
be a partial agonist for human FXR by activating BSEP and
suppressing CYP7A1 [67]. Results in FXR−/− mice, however
imply that UDCA effects are largely independent of FXR [75]. In
addition to these transcriptional effects, UDCA also stimulates
vesicular exocytosis and insertion of canalicular transport systems
into the canalicular membrane in rats, changes which are medi-
ated by activation of Ca2+-dependent protein kinase C and mito-
gen-activated protein kinases [227,230]. Moreover, UDCA may
also directly stimulate canalicular transport function by inducing
phosphorylation of ABC transporters [234]. Despite the marked
effects of UDCA on ABC transporter expression and function in
normal rodents, UDCA-feeding in cholestatic (common bile duct-
ligated) mice results only in a mild further induction of hepatic
and renal Mrps, while still having a marked stimulatory effect on
Bsep expression [196]. Thus, UDCA treatment is not able to
significantly enhance the intrinsic adaptive ABC transporter re-
sponse under cholestatic conditions in mice. Therefore more
specific stimulators/inducers of a coordinated detoxification and
alternative escape systems are desirable.
FXR agonists could overcome the reduction of bile flow in
cholestasis via stimulation of BSEP (increasing bile acid-
dependent bile flow) andMRP2 (increasing bile acid-independent
bile flow) (Fig. 6) [68,72,235]. However, it may be simplistic to
treat cholestasis merely by stimulation of bile flow, particularly in
the presence of biliary obstruction. For example, application of
high, choleretic doses of UDCA (a weak partial FXR agonist) in
CBDL mice results in increased biliary pressure with rupture of
cholangioles resulting in aggravation of bile infarcts and an in-
creased mortality [23]. Unfortunately, many clinically relevant
chronic cholestatic liver diseases such PSC have a significant
obstructive component which, however, may evolve slowly (inagonists should counteract cholestasis by limiting bile acid uptake systems via
and Oatp1 (Oatp1a1), respectively. Simultaneously, FXR agonists stimulate bile
ucedMrp2. In addition to their multiple effects on detoxification enzymes, PXR
sts preferentially induce Mrp2 and both alternative basolateral export pumps for
; dotted lines and arrows, PXR effects; broken lines and arrows, CAR effects.
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permit more time for pharmaceutical intervention. However, FXR
agonists may also support some adaptive reactions of the chole-
static hepatocyte which would be predicted to limit the hepato-
cellular bile acid burden (i.e. downregulation of Ntcp, Oatp1
(Oatp1a1) as well as Cyp7a1 and Cyp8b1 and upregulation of
Mrp2 and Bsep [69,75,194,233]. First experiments with synthetic
FXR agonists in cholestatic rodent models have been promising.
InCBDL rats the FXR agonist GW4064 reduced biochemical and
histomorphological markers of liver injury, which was accompa-
nied by induction of Bsep,Mdr2 and ShpmRNAand reduction of
Cyp7a1 and Cyp8b1 mRNA levels. [236]. However, serum
markers of cholestasis (i.e. alkaline phosphatase, bilirubin and
bile acids) were not reduced. In rats treated with ANIT, as a model
for intrahepatic cholestasis, GW4064 reduced serum markers of
liver injury and cholestasis and improved histology by stimulating
transport and metabolic systems [236]. In the LCA rat model of
intrahepatic cholestasis, the strong half-synthetic FXR agonist
6α-ethyl-chenodeoxycholic acid (6-ECDCA) reversed impair-
ment of bile flow and improved liver cell necrosis, effects which
were not observed after treatment with the strongest endogenous
FXR ligand, CDCA [237]. 6-ECDCA also has antifibrotic effects
of in vitro and in vivo in rats, suggesting that FXR (via SHP and
AP-1) may suppress fibrogenesis in hepatic stellate cells [238].
Improvement and induction of FXR target genes was also
observed in ethinyestradiol induced cholestasis after 6-ECDCA
treatment in rats [239]. However, the wider therapeutic use of
FXR agonists could be jeopardized by interfering FXR functions
in lipid homeostasis such as HDL and triglyceride metabolism
[235].
PXR and CAR agonists have been used for treatment of human
cholestatic disorders and jaundice long before their mode of action
was clarified. PXR and CAR may be rational therapeutic targets
since – in contrast to FXR – they are not reduced during chole-
static conditions in mice [49,240] (Wagner, Trauner unpublished
observations). The human PXR agonist rifampicin was predom-
inantly used for the treatment of pruritus, but in most cases effects
on cholestatic parameters in PBC were only minor and drug-
related side effects were observed in up to 10% of treated patients
[241–243]. The potent rodent PXR ligand PCN was reported to
protect against LCA induced liver injury on various levels, effects,
which were not seen after treatment of PXR−/− mice. These pro-
tective effects may bemediated by induction of Cyp3a11, which is
supposed to hydroxylate hydrophobic bile acids [58], induction of
Oatp2 (Oatp1a4) and downregulation of Cyp7a1 [56], and in-
duction of bile acid sulfating sulfotransferase (Sult2a1) together
with its sulfonyl donor 3′-phosphoadenosine 5′-phosphosulfate
synthetase 2 (PAPSS2) [244]. All of these target geneswere shown
to be directly activated via PXR. In addition, PXR activationmight
contribute to reduced injury in mice by its effects on bilirubin
glucuronidating Ugt1a1 and exportingMrp2 [72,245]. In common
bile duct ligated mice PCN pretreatment led to a significant re-
duction of serum bile acid levels, which was accompanied by
increased relative levels of polyhydroxylated bile acids in serum
and urine [114]. Administration of the human PXR agonist rifam-
picin to healthy human volunteers significantly induced UGT1A1
andMRP2 expression which reduced serum bilirubin levels [229].Moreover, rifampicin potently induced CYP3A4 expression
resulting in increased bile acid hydroxylation [229]. In addition,
a recent study reported that PCN has also antifibrotic effects by
inhibiting the trans-differentiation of quiescent hepatic stellate
cells into a myofibroblast-like phenotype and thereby reducing α-
smooth muscle antigen and collagen as fibrotic markers [246].
These effects, however were partially attributed to the proliferative
potential of PCN and suggested to act via PXR-dependent and
-independent pathways.
Certain traditional Chinese herbs are potent CAR activators
and have long been used for treatment of neonatal jaundice [247].
In mice treatment with CAR agonists (TCPOBOP and pheno-
barbital) drastically reduced serum levels of infused bilirubin via
induction of a cascade involving hepatocellular bilirubin uptake
(Slc21a5), binding to glutathione-S transferases (Gsta1, Gsta2),
glucuronidation of bilirubin (Ugt1a1) and canalicular excretion
via Mrp2 [59]. The prototypic CAR agonist phenobarbital is also
an “old fashioned” treatment used in several human cholestatic
disorders, again predominantly for the treatment of pruritus [248–
250]. In PBC, studies using phenobarbital showed partial im-
provement of cholestasis in selected patients [249,251,252]. CAR
agonists were shown to protect against LCA-induced toxicity in
mice primarily by induction of Sult2a1/2a9 and PAPSS2 gene
expression with subsequent LCA sulfatation rather than induction
of Cyp3a11 and hydroxylation [253]. It has also been proposed
that sulfation of bile acids via Sult2a1 and subsequent export via
sulfated bile acid transporting Mrp4 is controlled by CAR in a
coordinated fashion [60,114]. A study exploring cholic acid
toxicity in FXR−/− and PXR−/− mice revealed that CAR agonists
canmitigate cholic acid toxicity evenwhen both classical bile acid
receptors are knocked-out; this may be explained by induction a
cascade of bile acid/bilirubin detoxifying enzymes and transpor-
ters [49], strengthening the fundamental role of CAR in bile acid
detoxification. The use of PXR and CAR double knock-out mice
in LCA induced injury underlined the essential role of both
nuclear receptors for xenobiotic and bile acid metabolism, since
injury was most aggravated in the double knock-out mice [120,
254]. In the CBDL model, treatment of mice with CAR agonists
reduces serumbilirubin and bile acid levels, the latter via enhanced
hydroxylation resulting in a more effective renal clearance [114].
These findings may again be explained by a coordinated stimu-
lation of the orchestra of phase I (Cyp2b10, Cyp3a11) and phase II
(Sult2a1, Ugt1a1) detoxification enzymes together with alternative
basolateral overflow systems (Mrp3, Mrp4), while classical ortho-
grade bile acid and organic anion transporters (Ntcp,Oatp1,Oatp4,
Bsep) remain unaffected [114]. Thus, the use of specific agonists
for PXR or CAR for the treatment of human cholestasis may be
promising. However one has to keep in mind that these drugs not
only detoxify but also can toxify [114,120,255] by interactingwith
several other endogenous metabolic pathways (e.g., thyroid hor-
mone metabolism pathway [256] or influencing drug metabolism
[58]). Another caveat is the liver tumor promoting potential of PB
via CAR [257] and the potential role of PXR in the pathogenesis of
endometrial cancer [258].
Peroxisome proliferator-activated receptor alpha (PPARα)
agonists are also promising therapeutic approaches in human
cholestatic liver disease since fibrates or statins showed beneficial
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minases in PBC patients [259–262]. A potential mode of action of
PPARα agonists in cholestasis could be linked to their potential to
stimulate the canalicular phospholipid flippase Mdr2, thus
protecting the bile duct epithelium by counteracting the detergent
effects of bile acids via enhanced biliary phospholipid excretion
with subsequent formation of mixed micelles [263–267]. In
addition, repression of CYP7A1 (so far only shown for fibrates
[268]), or pleiotropic anti-inflammatory effects may contribute to
potential therapeutic effects [269].
Peroxisome proliferator-activated receptor gamma (PPARγ)
agonists have originally been introduced as insulin-sensitizing,
antidiabetic drugs, but also have broader effects on lipid meta-
bolism, inflammation and fibrosis [270]. As such PPARγ
agonists have antifibrotic effects in patients with non-alcoholic
steatohepatitis and in vivo and in vitro experimental models of
hepatic fibrosis [271,272,272]. PPARγ overexpression led to a
significant decrease of collagen type 1A1 and tissue inhibitor of
metalloproteinases 2 with subsequent reduction of hydroxypro-
line in 14d CBDL rats [273]. These antifibrotic effects may be
mediated to a certain degree via FXR and SHP [274]. Moreover,
rosiglitazone was demonstrated to reverse LPS-mediated down-
regulation of hepatic transporters implying a role for its potential
use in inflammation-mediated liver diseases [275].
Corticosteroids have been used both in acute human cholestasis
(steroid-induced normalization of liver function tests or “steroid
whitewash” in drug- and inflammation-induced cholestasis) and
chronic cholestatic disorders such as PBC (e.g., prednisolone or
budesonide) [276–278]. In addition to their anti-inflammatory and
immune-modulatory effects, part of their effects could bemediated
via transporter and enzyme alterations (possibly by targeting the
glucocorticoid receptor, although this has so far only been shown
in promoter studies in vitro for intestinal ASBT [279] and NTCP
[280]). Corticosteroids induceMrp2 and Bsep and counteract their
downregulation after endotoxin treatment in vitro [167,281]. Re-
cently, omeprazole has been shown to stimulate MRP3 in human
liver [282].
In summary nuclear receptors are promising targets for
modulating transporter expression (Fig. 6). The future should
bring usmore gene-selective agonists in order to specifically target
subsets of genes and separate “wanted” from “unwanted” effects.
10. Conclusions
Transcriptional regulation of hepatic organic anion transport-
er regulation is key for understanding the pathophysiology of
cholestasis. While some of the changes may contribute to or
maintain cholestasis, others (especially with prolonged duration
of cholestasis) may be the result of adaptive processes which aim
at limiting the extent of the cholestatic liver injury. The
underlying molecular mechanisms are complex and our insights
are still incomplete since major parts of the puzzle are still
missing. The growing information on the transcriptional
regulation of hepatobiliary transport systems should lead to the
identification of novel therapies. Nuclear receptors and their
target genes represent worthwhile therapeutic targets for
cholestatic liver diseases.Acknowledgment
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